Company intelligence / Profile preview

Alpharma USPD

Bridgewater, New Jersey, United States

Ownership: Private
Employees: ~3000
Development stage: Other

Overview

Alpharma was a global specialty pharmaceutical company focused on the development, manufacture, and marketing of human and animal health products. The company's United States Pharmaceutical Division (USPD) was a leader in the generic liquid and topical pharmaceutical market and also marketed specialty brand-name products. Its most notable products included Kadian, an extended-release morphine sulfate for chronic pain, and the Flector Patch, a topical NSAID for acute pain. Alpharma was acquired by King Pharmaceuticals in 2008 for approximately $3.6 billion, and King was subsequently acquired by Pfizer in 2011.

Therapeutic areas: ImmunologyNeurologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

IBSA Institut Biochimique

Beyond the preview

Go deeper on Alpharma USPD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpharma USPD.

Explore the full profile